Aardvark Therapeutics (NASDAQ:AARD) Stock Price Up 4.6% – What’s Next?

Aardvark Therapeutics, Inc. (NASDAQ:AARD) rose 4.6% during mid-day trading on Thursday . The stock traded as high as $3.66 and last traded at $3.64. Approximately 91,621 shares changed hands during mid-day trading, a decline of 49% from the average daily volume of 178,192 shares. The stock had previously closed at $3.48.

Analysts Set New Price Targets

AARD has been the topic of several analyst reports. BTIG Research lowered shares of Aardvark Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 15th. Oppenheimer cut their price target on shares of Aardvark Therapeutics from $35.00 to $21.00 and set an “outperform” rating on the stock in a report on Monday, March 2nd. Morgan Stanley reaffirmed an “underweight” rating and issued a $3.00 price target (down from $7.00) on shares of Aardvark Therapeutics in a report on Friday, May 15th. B. Riley Financial cut their price target on shares of Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Finally, Royal Bank Of Canada lowered shares of Aardvark Therapeutics from an “outperform” rating to a “sector perform” rating and cut their price target for the stock from $18.00 to $6.00 in a report on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $19.70.

Aardvark Therapeutics Price Performance

The stock has a market capitalization of $85.10 million, a PE ratio of -1.21 and a beta of 4.47. The business’s fifty day moving average price is $4.69 and its two-hundred day moving average price is $8.86.

Aardvark Therapeutics (NASDAQ:AARD) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.99) earnings per share for the quarter. As a group, equities research analysts anticipate that Aardvark Therapeutics, Inc. will post -3.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aardvark Therapeutics

A number of large investors have recently made changes to their positions in AARD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Aardvark Therapeutics during the second quarter valued at $42,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Aardvark Therapeutics during the fourth quarter valued at $47,000. Persistent Asset Partners Ltd acquired a new position in Aardvark Therapeutics during the fourth quarter valued at $56,000. New York State Common Retirement Fund acquired a new position in Aardvark Therapeutics during the second quarter valued at $99,000. Finally, MetLife Investment Management LLC acquired a new position in Aardvark Therapeutics during the fourth quarter valued at $102,000.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (ROR?). ROR? plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective ROR? inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.